Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Morningstar report on TD Waterhouse

<< Previous

Bullboard Posts

Next >>

Comment by money4golfon Oct 04, 2024 10:03pm

180 Views

Post# 36254205

RE:Morningstar report on TD Waterhouse

Must be alot of work to keep supressing the share price!
AP is probably right, one more round of financing....

Valuation as of 3 Oct 2024
Spectral Medical achieves a 3-star quantitative star
rating based on Morningstar's equity model. This
reflects the company's valuation and uncertainty
scores under this assessment system.
The Quantitative Fair Value estimate is 1.72, above
the previous closing price of 0.59. The stock has
been trading between a 65.62% discount and
6.98% premium to its quantitative fair value over
the past year.
Fair ValueQoant
1.80

money4golf wrote: I like reading this instead of watching TD and Scotia seemingly bring the price down....
This is on the TD Waterhouse website last report.

Quantitative Equity Research Report | Release: 27 Sep 2024, 02:58 UTC | Reporting Currency: CAD | Trading Currency: CAD | Exchange: TORONTO STOCK EXCHANGE
Spectral Medical Inc EDT QQQ Q 26 Sep 2024 22:40, UTC
Fair Value $1.62
Valuation as of 26 Sep 2024
Morningstar affirms a 3-star quantitative rating for
Spectral Medical. We calculate this outcome using
the company's underlying model-driven valuation
and uncertainty scores.
The stock's last closing price was 0.62, a discount
of 58.76% to its Quantitative Fair Value estimate of
$1.50.